| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 212,563 | 383,724 | 1,398,732* | 504,387 |
| Selling, general and administrative (including related party amounts of 428,966 and 619,549 for the three and six months ended june 30, 2026, respectively, and 0 for the three and six months ended june 30, 2025) | 2,801,004 | 1,542,658 | 1,074,763* | 1,256,284 |
| Total operating expenses | 3,013,567 | 1,926,382 | 2,473,495 | 1,760,671 |
| Loss from operations | -3,013,567 | -1,926,382 | -2,473,495* | -1,760,671 |
| Interest income | 46,504 | 78,676 | 4,561* | 68,682 |
| Net loss | -2,967,063 | -1,847,706 | -2,468,934 | -1,691,989 |
| Basic EPS | -0.74 | -0.48 | -3.403 | -1.65 |
| Diluted EPS | -0.74 | -0.48 | -3.403 | -1.65 |
| Basic Average Shares | 4,022,143 | 3,858,921 | 725,613 | 1,026,457 |
| Diluted Average Shares | 4,022,143 | 3,858,921 | 725,613 | 1,026,457 |
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)